
|Articles|November 1, 2012
FDA Approves Single REMS for Mycophenolate Class of Drugs
FDA approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for all mycophenolate-containing prescription drugs at the end of September.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
2
Zepbound Lowers Health Care Costs in Older Adults With Obesity
3
Ixekizumab, Tirzepatide Maintains Efficacy in Psoriatic Disease
4
Measles Resurgence Exposes US Vaccine Policy Risks, Experts Warn
5






































